HighTower Advisors
NKTR icon

HighTower Advisors’s Nektar Therapeutics NKTR Stock Holding History

HighTower Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,241
Closed -$22K – 3893
2024
Q2 		$22K Sell
1,241
-43
-3% -$906 ﹤0.01% 3393
2024
Q1 		$18K Sell
1,284
-32
-2% -$335 ﹤0.01% 3362
2023
Q4 		$11K Hold
1,316
– – ﹤0.01% 3433
2023
Q3 		$11K Buy
1,316
+33
+3% +$318 ﹤0.01% 3380
2023
Q2 		$11K Sell
1,283
-142
-10% -$1.51K ﹤0.01% 3297
2023
Q1 		$15K Hold
1,425
– – ﹤0.01% 3170
2022
Q4 		$46K Buy
1,425
+7
+0.5% +$339 ﹤0.01% 3044
2022
Q3 		$68K Buy
1,418
+736
+108% +$43.8K ﹤0.01% 2837
2022
Q2 		$40K Buy
+682
New +$43K ﹤0.01% 2929
2022
Q1 		– Sell
-702
Closed -$143K – 3586
2021
Q4 		$143K Sell
702
-134
-16% -$29.1K ﹤0.01% 2857
2021
Q3 		$226K Sell
836
-984
-54% -$237K ﹤0.01% 2623
2021
Q2 		$466K Sell
1,820
-132
-7% -$36.5K ﹤0.01% 2088
2021
Q1 		$593K Sell
1,952
-90
-4% -$28K ﹤0.01% 1881
2020
Q4 		$522K Buy
2,042
+408
+25% +$105K ﹤0.01% 1627
2020
Q3 		$402K Sell
1,634
-64
-4% -$20.1K ﹤0.01% 1675
2020
Q2 		$589K Sell
1,698
-20
-1% -$6.24K ﹤0.01% 1380
2020
Q1 		$460K Sell
1,718
-57
-3% -$17.6K ﹤0.01% 1363
2019
Q4 		$569K Buy
1,775
+84
+5% +$24.4K ﹤0.01% 1386
2019
Q3 		$462K Buy
1,691
+168
+11% +$61.6K ﹤0.01% 1555
2019
Q2 		$811K Sell
1,523
-72
-5% -$36.1K ﹤0.01% 1296
2019
Q1 		$805K Buy
1,595
+174
+12% +$103K 0.01% 1230
2018
Q4 		$700K Sell
1,421
-65
-4% -$39.2K 0.01% 1190
2018
Q3 		$1.36M Sell
1,486
-67
-4% -$57.2K 0.01% 998
2018
Q2 		$1.14M Buy
1,553
+324
+26% +$374K 0.01% 1061
2018
Q1 		$1.96M Sell
1,229
-637
-34% -$821K 0.02% 815
2017
Q4 		$1.67M Sell
1,866
-538
-22% -$318K 0.01% 883
2017
Q3 		$866K Buy
2,404
+216
+10% +$67.6K 0.01% 1171
2017
Q2 		$643K Buy
2,188
+1,073
+96% +$310K 0.01% 1259
2017
Q1 		$391K Buy
1,115
+71
+7% +$16K ﹤0.01% 1439
2016
Q4 		$192K Buy
1,044
+314
+43% +$63.8K ﹤0.01% 1690
2016
Q3 		$189K Buy
+730
New +$188K ﹤0.01% 1663
2016
Q2 		– Sell
-692
Closed -$147K – 1941
2016
Q1 		$147K Buy
+692
New +$133K ﹤0.01% 1860

Other funds holding NKTR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

HighTower Advisors's NKTR Position: Q3 2024 in Review

HighTower Advisors sold out of Nektar Therapeutics (NKTR) in Q3 2024, closing a stake of 1,241 shares — an estimated $22K sold.

HighTower Advisors first reported a position in NKTR in Q1 2016 and held it in 32 quarters. The position peaked at $1.96M in Q1 2018. 138 funds tracked by Wall St. Rank hold NKTR as of Q3 2024.

  • HighTower Advisors reported no remaining Nektar Therapeutics position as of Q3 2024 after selling out during the quarter.
  • HighTower Advisors sold 1,241 Nektar Therapeutics shares in Q3 2024, an estimated $22K.
  • HighTower Advisors first reported a position in Nektar Therapeutics in Q1 2016 and held it in 32 quarters.
  • HighTower Advisors's Nektar Therapeutics position peaked at $1.96M in Q1 2018.
  • 138 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2024.

Based on HighTower Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.